Markets · Asia · KSE

326030.KS SK Biopharm

₩72,700 -4.34%

Asia · Health Care

Log

Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.

-4.34%

YTD

-30.00%

P/E

—

P/B

—

ROE

—

Div yield

—

Beta

0.68

Market cap

—

RSI (14)

Next earnings

—

Previous session

close of Oct 8, 2026 · EOD, no live order book

Open

₩75,500

₩72,700

VWAP (n/a)

—

Day high

₩75,600

Day low

₩72,700

Volume

156K

VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.

Latest headlines

1ST Biotherapeutics and SK Biopharmaceuticals Announce Exclusive Global License Agreement for Parkinson's Disease Candidate ‘1ST-104’

Yahoo Finance · Sep 17

BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

Yahoo Finance · Aug 27

Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal

Yahoo Finance · Aug 26

SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'

Yahoo Finance · Aug 26

Insilico Medicine, SK Biopharmaceuticals strike $2.5B AI drug discovery deal targeting neuroimmune therapies

Yahoo Finance · Jun 22

SK Biopharmaceuticals opens New Jersey hub for Korean biotech firms

Yahoo Finance · Jun 8

Headlines via Yahoo Finance · links open the source · not an endorsement.

Research & reports

TradingView ↗

Charts & analysis

Yahoo Finance ↗

Quote & news

External resources — availability and opinions are theirs, not ours.

This is reference data for your own analysis — not a recommendation to buy or sell 326030.KS. Try it in the Lab to size a position and see the risk.